Company Overview
Snapshot
Founded in January 2014, BioEye is led by co-founder Dovi Yellen and operates with 1–10 employees. The company has secured $200K in total capital across one funding round from one investor, Office of the Chief Scientist. BioEye is currently in the clinical trial phase for its products.
Business overview
BioEye specializes in digital healthcare, leveraging a mobile eye-tracking application to monitor cognitive states. The company's core technology utilizes high-quality eye biomarkers, such as eye movement, blink rate, and pupil size, captured via a mobile app. This data is then sent to a cloud-based big-data repository where machine-learning algorithms detect abnormal trends and provide early detection of cognitive decline. BioEye serves markets within the Health Tech & Life Sciences sector, specifically targeting digital medical diagnostics for patients and healthcare providers, and operates on both B2C and B2B business models.
Log in to access full profile ›Company Intelligence Q&A
- What is BioEye's primary focus?
- BioEye focuses on monitoring cognitive states through a mobile eye-tracking application, providing early detection of cognitive decline and enabling effective intervention using eye biomarkers and machine learning.
- When was BioEye founded?
- BioEye was founded in January 2014.
- Who is a co-founder of BioEye?
- Dovi Yellen is a co-founder and CTO of BioEye.
- What is BioEye's current product development stage?
- BioEye's products are currently in the clinical trial stage, as of 2023. This involves testing the mobile eye-tracking application for monitoring cognitive states.
- What is BioEye's business model?
- BioEye operates with both B2C and B2B business models.